This latter can be related to the AML genetic background as a recent study showed that the proportion of proliferating LSC increased within AML samples with core-binding factor (CBF) mutations and sensitive to chemotherapy as opposed to poor prognosis samples carrying FLT3-ITD mutation and normal karyotype. The gene discussed is FLT3; the disease is acute myeloid leukemia.